NASDAQ:NUVL 17 June 2026 - 27 June 2026

GSK plc ended a thin news week with a 3% gain, leaving the London-listed drugmaker close to the 2,000p line and giving investors a cleaner read on its biggest question: whether the market is starting to accept an £8 billion oncology bet that looked large for a company long viewed as a vaccines and HIV name. London trading was shut on Saturday. The London Stock Exchange lists June 27 as closed, after a normal Friday session from 8:00 a.m. to 4:30 p.m. BST. GSK’s last London trade was Friday’s 1,983.00p close, down 0.03% on the day, after a 1,945.50p-1,995.50p range.

GSK plc traded lower in London on Friday. The day marked the final scheduled round of its £2 billion share buyback, but the $10.6 billion Nuvalent tender offer has become a bigger weight than the daily support from the buyback. The London Stock Exchange was open at the dateline time; its June 26 session runs from 0800 to 1630 BST. GSK traded at 1,951.50p on the sell side and 1,952.00p to buy, down 32p, or 1.61%, according to AJ Bell. The stock’s market cap was about £78.21 billion. A £180 million final buyback at these levels would be close to 9.2 million shares, or about 0.2% of the company’s equity. Meanwhile, the Nuvalent bid, valued by GSK at £8.0 billion,

GSK shares didn’t move much Thursday as the company kicked off its $124-per-share cash tender offer for Nuvalent. New filings from Nuvalent spell out the sales growth GSK needs to make this its biggest purchase in over ten years. Nuvalent is projecting net revenue of $14 million in 2026, climbing to $1.35 billion by 2030 and $2.53 billion for 2031, according to its unaudited, risk-adjusted management forecast. EBIT is negative until 2029, then expected to hit $1.50 billion by 2031. Unlevered free cash flow stays below zero through 2029, then moves up to $275 million in 2030, hitting $936 million in 2031.

GSK shares traded higher in London on Wednesday, even as the UK blue-chip index edged down. Investors kept looking at the drugmaker’s plan to strengthen its cancer unit with a planned buyout of U.S. biotech Nuvalent. GSK shares traded at 1,962p, up 0.62%, at 12:41 p.m. in London after opening at 1,948.5p. The FTSE 100 slipped 0.14% earlier as traders looked at UK inflation data ahead of the Bank of England’s rate call.